Major PBS listings to benefit lung cancer and cholesterol patients

Two major new listings on the Pharmaceutical Benefits Scheme (PBS) have the potential to extend the lives of Australians with advanced lung cancer and those at risk of a heart attack, saving patients up to nearly $190,000 a year.

Page last updated: 29 October 2018

Major PBS listings to benefit lung cancer and cholesterol patients (PDF 262 KB)

Two major new listings on the Pharmaceutical Benefits Scheme (PBS) have the potential to extend the lives of Australians with advanced lung cancer and those at risk of a heart attack, saving patients up to nearly $190,000 a year.

November is Lung Cancer Awareness Month and from 1 November patients with advanced lung cancer will have the treatment Keytrudaź subsidised for first-line treatment of metastatic non-small cell lung cancer (NSCLC).

Without PBS subsidy it would cost over $11,300 per script or $188,000 a year. Patient will now pay a maximum of $39.50 per script or just $6.40 per script for concessional patients, including pensioners.

This listing means that for the first time eligible patients with advanced lung cancer can avoid chemotherapy and be treated with this novel immunotherapy treatment Keytrudaź. It will benefit around 850 patients a year.

Keytrudaź is an immunotherapy medicine working with a patient’s own immune system to recognise cancer cells and destroy them. Clinical trials of Keytrudaź for lung cancer has shown that some patients became virtually cancer free after treatment.

This medicine is already listed on the PBS for classical Hodgkin’s lymphoma and unresectable Stage III or Stage IV malignant melanoma.

The Liberal National Government is also listing Repathaź from November 1 for the treatment of familial hypercholesterolaemia, which is a genetic high cholesterol condition.

More than 6,000 people with the condition, who are at risk of having a heart attack or stroke at an early age, will benefit from the treatment.

Patients would normally pay around $630 a script, or more than $8000 a year. With its listing on the PBS, eligible patients will pay a maximum of $39.50 per script for Repatha or just $6.40 with a concession card.

These listings with help the thousands of Australians and their families fighting lung cancer and the devastating impact of heart disease.

Our Government’s strong economic management means weare providing Australian patients with access to life-saving and life-changing medicines quicker than ever before.

We are now making on average one new or amended PBS listing every single day. Only the Coalition can be trusted to deliver for Australian patients.

Since coming into Government, the Coalition has helped improve the health of Australians by subsidising almost $10 billion worth of new medicines.

The independent Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listings announced today.

The Committee is independent of Government by law and in practice. By law the Federal Government cannot list a new medicine without a positive recommendation from PBAC.

Unlike Labor, we are subsidising all drugs recommended by the independent medical experts.

In the Budget we announced our commitment to invest $2.4 billion in new medicines to build on our commitment to guarantee those essential services that all Australians rely on.

Our commitment to the PBS is rock solid. Together with Medicare, it is a foundation of our world-class health care system.

Authorised by Greg Hunt MP, Liberal Party of Australia, Somerville, Victoria.

(ENDS)

Top of Page